Moreover, tau imaging seems to be a promising tool, while PET with dopaminergic (e.g., 18F-fluoro-L-dopa (6FD) and 11C-raclopride) tracers reveals uptake abnormalities different from those of Parkinson’s disease (PD) [47]. Here, MAPT is linked to Parkinson disease.